These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

405 related articles for article (PubMed ID: 23564777)

  • 1. Combining celecoxib with sorafenib synergistically inhibits hepatocellular carcinoma cells in vitro.
    Morisaki T; Umebayashi M; Kiyota A; Koya N; Tanaka H; Onishi H; Katano M
    Anticancer Res; 2013 Apr; 33(4):1387-95. PubMed ID: 23564777
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combining sorafenib with celecoxib synergistically inhibits tumor growth of non-small cell lung cancer cells in vitro and in vivo.
    Zhang H; Li Z; Wang K
    Oncol Rep; 2014 Apr; 31(4):1954-60. PubMed ID: 24549815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sorafenib enhances the chemotherapeutic efficacy of S-1 against hepatocellular carcinoma through downregulation of transcription factor E2F-1.
    Zhai JM; Yin XY; Lai YR; Hou X; Cai JP; Hao XY; Liang LJ; Zhang LJ
    Cancer Chemother Pharmacol; 2013 May; 71(5):1255-64. PubMed ID: 23435877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 2-Methoxyestradiol synergizes with sorafenib to suppress hepatocellular carcinoma by simultaneously dysregulating hypoxia-inducible factor-1 and -2.
    Ma L; Li G; Zhu H; Dong X; Zhao D; Jiang X; Li J; Qiao H; Ni S; Sun X
    Cancer Lett; 2014 Dec; 355(1):96-105. PubMed ID: 25218350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potent cell growth inhibitory effects in hepatitis B virus X protein positive hepatocellular carcinoma cells by the selective cyclooxygenase-2 inhibitor celecoxib.
    Xie H; Gao L; Chai N; Song J; Wang J; Song Z; Chen C; Pan Y; Zhao L; Sun S; Wu K; Feitelson MA; Liu J; Fan D
    Mol Carcinog; 2009 Jan; 48(1):56-65. PubMed ID: 18506760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel combination of sorafenib and celecoxib provides synergistic anti-proliferative and pro-apoptotic effects in human liver cancer cells.
    Cervello M; Bachvarov D; Lampiasi N; Cusimano A; Azzolina A; McCubrey JA; Montalto G
    PLoS One; 2013; 8(6):e65569. PubMed ID: 23776502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic anticancer activity of 20(S)-Ginsenoside Rg3 and Sorafenib in hepatocellular carcinoma by modulating PTEN/Akt signaling pathway.
    Lu M; Fei Z; Zhang G
    Biomed Pharmacother; 2018 Jan; 97():1282-1288. PubMed ID: 29156516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic Antitumor Effect of Sorafenib in Combination with ATM Inhibitor in Hepatocellular Carcinoma Cells.
    Liu J; Liu Y; Meng L; Ji B; Yang D
    Int J Med Sci; 2017; 14(6):523-529. PubMed ID: 28638267
    [No Abstract]   [Full Text] [Related]  

  • 9. PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation.
    Gedaly R; Angulo P; Hundley J; Daily MF; Chen C; Evers BM
    J Surg Res; 2012 Aug; 176(2):542-8. PubMed ID: 22261591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Meloxicam combined with sorafenib synergistically inhibits tumor growth of human hepatocellular carcinoma cells via ER stress-related apoptosis.
    Zhong J; Xiu P; Dong X; Wang F; Wei H; Wang X; Xu Z; Liu F; Li T; Wang Y; Li J
    Oncol Rep; 2015 Oct; 34(4):2142-50. PubMed ID: 26252057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclooxygenase-2 promotes hepatocellular carcinoma cell growth through Akt activation: evidence for Akt inhibition in celecoxib-induced apoptosis.
    Leng J; Han C; Demetris AJ; Michalopoulos GK; Wu T
    Hepatology; 2003 Sep; 38(3):756-68. PubMed ID: 12939602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation.
    Chen KF; Yu HC; Liu TH; Lee SS; Chen PJ; Cheng AL
    J Hepatol; 2010 Jan; 52(1):88-95. PubMed ID: 19913321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Arsenic trioxide potentiates the anti-cancer activities of sorafenib against hepatocellular carcinoma by inhibiting Akt activation.
    Zhai B; Jiang X; He C; Zhao D; Ma L; Xu L; Jiang H; Sun X
    Tumour Biol; 2015 Apr; 36(4):2323-34. PubMed ID: 25416439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A polymeric nanoparticle formulation of curcumin in combination with sorafenib synergistically inhibits tumor growth and metastasis in an orthotopic model of human hepatocellular carcinoma.
    Hu B; Sun D; Sun C; Sun YF; Sun HX; Zhu QF; Yang XR; Gao YB; Tang WG; Fan J; Maitra A; Anders RA; Xu Y
    Biochem Biophys Res Commun; 2015 Dec; 468(4):525-32. PubMed ID: 26482853
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metformin sensitizes sorafenib to inhibit postoperative recurrence and metastasis of hepatocellular carcinoma in orthotopic mouse models.
    You A; Cao M; Guo Z; Zuo B; Gao J; Zhou H; Li H; Cui Y; Fang F; Zhang W; Song T; Li Q; Zhu X; Yin H; Sun H; Zhang T
    J Hematol Oncol; 2016 Mar; 9():20. PubMed ID: 26957312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sorafenib and FH535 in combination act synergistically on hepatocellular carcinoma by targeting cell bioenergetics and mitochondrial function.
    Turcios L; Vilchez V; Acosta LF; Poyil P; Butterfield DA; Mitov M; Marti F; Gedaly R
    Dig Liver Dis; 2017 Jun; 49(6):697-704. PubMed ID: 28179093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sorafenib increases efficacy of vorinostat against human hepatocellular carcinoma through transduction inhibition of vorinostat-induced ERK/NF-κB signaling.
    Hsu FT; Liu YC; Chiang IT; Liu RS; Wang HE; Lin WJ; Hwang JJ
    Int J Oncol; 2014 Jul; 45(1):177-88. PubMed ID: 24807012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bufalin Reverses Resistance to Sorafenib by Inhibiting Akt Activation in Hepatocellular Carcinoma: The Role of Endoplasmic Reticulum Stress.
    Zhai B; Hu F; Yan H; Zhao D; Jin X; Fang T; Pan S; Sun X; Xu L
    PLoS One; 2015; 10(9):e0138485. PubMed ID: 26381511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of PI3K/mTOR inhibition in combination with sorafenib in hepatocellular carcinoma treatment.
    Gedaly R; Angulo P; Chen C; Creasy KT; Spear BT; Hundley J; Daily MF; Shah M; Evers BM
    Anticancer Res; 2012 Jul; 32(7):2531-6. PubMed ID: 22753710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma.
    Ou DL; Shen YC; Liang JD; Liou JY; Yu SL; Fan HH; Wang DS; Lu YS; Hsu C; Cheng AL
    Clin Cancer Res; 2009 Sep; 15(18):5820-8. PubMed ID: 19737956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.